Digestive Diseases Center "Gastro"
About Digestive Diseases Center "Gastro"
"Lielākais gastroenteroloģijas centrs Baltijā. 2021.gadā atzīmē savu 20 gadu jubileju. Nodrošina pilnu diagnostisko un ārstniecisko pasākumu spektru gremošanas sistēmas (barības vada, kuņģa, zarnu, žultsceļu, aizkuņģa dziedzera, aknu) slimību noteikšanai un ārstēšanai. Mūsu vērtības: - profesionalitāte it visā, ko mēs darām; - jaunākās paaudzes tehnoloģijas diagnostikā un ārstniecībā; - pacientu labsajūta un komforts."
- Top Sponsors
- Top Collaborators
- Trials By Phase
- Recruitment Status
- Top Conditions
- Intervention Types
- Top Intervention Names
- Trials By Gender
Lead Sponsor
# Trials
Celgene
6
Allergan
4
Eli Lilly and Company
3
Pfizer
3
Ferring Pharmaceuticals
2
Hoffmann-La Roche
2
Bausch Health Americas, Inc.
1
Janssen Research & Development, LLC
1
Javier P. Gisbert
1
Menarini Group
1
OSE Immunotherapeutics
1
Clinical Trials at Digestive Diseases Center "Gastro"
During the past decade, Digestive Diseases Center "Gastro" conducted 18 clinical trials. In the 10-year time frame, 18 clinical trials started and 15 clinical trials were completed, i.e. on
average, 83.3% percent of trials that started reached the finish line to date. In the past 5 years, 1 clinical trials started and 10 clinical trials were completed. i.e. 1000%
of trials that started reached the finish line.
Trials List
Trail ID
Brief Title
Start Date
Completion Date
Status
Enrollment
(CB-01-02/02) Randomized Placebo Controlled Trial of Budesonide-multi-matrix System (MMX™) 6 mg and 9 mg in Patients With Ulcerative Colitis
2008-06-01
2010-04-01
Completed
514
A Study Of Oral CP-690,550 As A Maintenance Therapy For Ulcerative Colitis
2012-07-20
2016-05-27
Completed
593
A Study Evaluating The Efficacy And Safety Of CP-690,550 In Patients With Moderate To Severe Ulcerative Colitis
2012-04-01
2015-05-01
Completed
614
Long-Term Study Of CP-690,550 In Subjects With Ulcerative Colitis
2012-10-01
2020-08-06
Completed
944
Selective 5-HT4 Receptor Agonist and Proton Pump Inhibitor (PPI) in Subjects With Gastroesophageal Reflux Disease (GERD)
2012-02-27
2013-05-14
Completed
480
Study for Participants With Ulcerative Colitis Previously Enrolled in Etrolizumab Phase II/III Studies
2014-09-15
2025-08-16
Active, not recruiting
1,822
A Study Comparing the Efficacy and Safety of Etrolizumab With Adalimumab and Placebo in Participants With Moderate to Severe Ulcerative Colitis (UC) in Participants Naive to Tumor Necrosis Factor (TNF) Inhibitors
2014-11-14
2020-05-25
Completed
358
Clinical Trials Sponsors and Collaborators
Out of the total clinical trials conducted in "Digestive Diseases Center "Gastro"" #1 sponsor was "Celgene" with 6 trials, followed by "Allergan" with 4 trials
sponsored, "Eli Lilly and Company" with 3 trials sponsored, "Pfizer" with 3 trials sponsored and "Ferring Pharmaceuticals"
with 3 trials sponsored. Other sponsors include 4 different institutions and
companies that sponsored additional 13 trials in total.
In terms of collaborators to trials, out of the total clinical trials conducted in "Digestive Diseases Center "Gastro""
#1 collaborator was "Cosmo Technologies Ltd" with 1 trials as a collaborator. Other collaborators include -1 different institutions and companies that were
collaborators in the rest 1 trials.
Clinical Trials Conditions at Digestive Diseases Center "Gastro"
According to Clinical.Site data, the most researched conditions in "Digestive Diseases Center "Gastro"" are
"Ulcerative Colitis" (13 trials), "Crohn Disease" (5 trials), "Gastroparesis" (4 trials), "Diabetes Mellitus" (3 trials) and "Colitis, Ulcerative" (1 trials). Many other conditions were trialed in "Digestive Diseases Center "Gastro"" in a lesser frequency.
Clinical Trials Intervention Types at Digestive Diseases Center "Gastro"
Most popular intervention types in "Digestive Diseases Center "Gastro"" are "Drug" (26 trials), "Other" (4 trials) and "Procedure" (1 trials). Other intervention types were less common.
The name of intervention was led by "Placebo" (17 trials), "GED-0301" (3 trials), "Ozanimod" (3 trials), "Relamorelin" (3 trials) and "Adalimumab" (2 trials). Other intervention names were less common.
Clinical Trials Genders at Digestive Diseases Center "Gastro"
The vast majority of trials in "Digestive Diseases Center "Gastro"" are
27 trials for "All" genders.
Clinical Trials Status at Digestive Diseases Center "Gastro"
Currently, there are NaN active trials in "Digestive Diseases Center "Gastro"".
undefined are not yet recruiting,
7 are recruiting,
3 are Active, not recruiting,
and undefined are Enrolling by invitation.
In total, there were 10 completed trials in Digestive Diseases Center "Gastro",
undefined suspended trials,
and 6 terminated clinical trials to date.
Out of the total trials that were conducted in Digestive Diseases Center "Gastro", 0 "Phase 1"
clinical trials were conducted, 4 "Phase 2" clinical
trials and 23 "Phase 3" clinical trials were conducted as
well. "Phase 4" trials included 0 trials, and there were
also 0 trials that are defined as “Not Applicable".